Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect

Arthritis Care and Research

Volumn 62, Issue 7, 2010, Pages 1002-1008

  Pagnoux, Christian ^a   Dechartres, Agnès ^a   Giraudeau, Bruno ^a   Seror, Raphaèle ^a   Guillevin, Loïc ^b   Ravaud, Philippe ^a  

^a INSERM   (France)

^b Assistance Publique Hôpitaux de Paris ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG USE; HUMAN; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADRENAL CORTEX HORMONES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; VASCULITIS;

EID: 77954252796     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20139     Document Type: Article

References (23)

1. Sachdeo R. Monotherapy clinical trial design. Neurology 2007;69:S23-7.
2. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum 2003;48:1481-3.
3. Ottolenghi L, Bertele V, Garattini S. Limits of add-on trials: antirheumatic drugs. Eur J Clin Pharmacol 2009;65:33-41.
4. Streiner DL. Alternatives to placebo-controlled trials. Can J Neurol Sci 2007;34 Suppl 1:S37-41.
5. Liang MH, Corzillius M, Bae SC, Fortin P, Esdaile JM, Abrahamowicz M. A conceptual framework for clinical trials in SLE and other multisystem diseases. Lupus 1999;8:570-80.
6. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
7. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134:657-62. (Pubitemid 32322244)
8. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
9. Team RDC, R Foundation for Statistical Computing. R: a language and environment for statistical computing. 2006. URL: http://www.R-project.org.
10. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150-4.
11. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, et al. Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 2007;92: 3013-8.
12. Hadidi T, Decker JL, El-Nagdy L, Samy M. Ineffectiveness of levamisole in systemic lupus erythematosus: a controlled trial. Arthritis Rheum 1981;24:60-3.
13. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
14. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
15. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepi-androsterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
16. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102. (Pubitemid 30434151)
17. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146: 631-9.
18. Corzillius M, Bae SC. Methodological issues of corticosteroid use in SLE clinical trials. Lupus 1999;8:692-7.
19. Hauschke D, Pigeot I. Establishing efficacy of a new experimental treatment in the 'gold standard' design. Biom J 2005; 47:782-98.
20. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:198-204.
21. Heller G. An adjustment for a post-randomization variable in the comparison of two treatments for survival. Stat Med 2001; 20:3475-85.
22. Proschan MA, Leifer E, Liu Q. Adaptive regression. J Biopharm Stat 2005;15:593-603.
23. Berger VW. A review of methods for ensuring the comparability of comparison groups in randomized clinical trials. Rev Recent Clin Trials 2006;1:81-6.